| Study (Ref.) |
# Enrolled |
Intervention |
Results |
ACOSOG-Z-9000 (DeMatteo RP B. K., 2013)
phase II prospective
single arm |
107 |
Adjuvant imatinib; 400 mg/day for 1 year |
OS-1 year 99 %, 3 years 97 %; RFS-1 year 94 %,
3 years 61 % |
AMC-ONCG1-0501( Kang B, 2009)(41); phase II prospective
Randomized |
47 |
Adjuvant imatinib; 400 mg/day until progression/ toxicity, or 2 years |
RFS—1 year, 98 %; 2 years,
93 % |
| ChiCTR-TCC00000582 (Li J, 2011)[42]; phase II Double blind randomized |
105 |
Imatinib or placebo/400 mg
Daily for 36 months |
RFS Imatinib vs. placebo
Year 1 – 100 % vs. 90 %
Year 2 – 96 % vs. 57 %
Year 3 – 89 % vs. 48 % |
| Kang et al ; Phase II Single arm (Kang B, 2009) |
47 |
Imatinib for 2 yrs or until
progression |
RFS- 2 years 93 % |
ACOSOG-Z9001 (DeMatteo RP B. K., 2009) ;
phase III prospective
randomized |
713 |
Adjuvant imatinib; 400 mg/day for 1 year |
1 year RFS; imatinib 98 %; placebo 83 % |
EORTC 62024;
Phase III prospective, randomized |
908 |
Adjuvant Imatinib 400 mg vs. observation for 2 years or until progression |
Imatinib failure-free survival 5 year 87% vs. 84% RFS 3-year 84 vs. 66 %
OS 5-year 100 vs. 99 % |
| SSG XVIII/AIO trial (Joensuu H E. M., 2012); Phase III prospective randomized |
400 |
Adjuvant Imatinib, 400 mg per day, orally for either 12 months or 36 months,
started within 12 weeks of surgery |
RFS 5-year 65.6% (36 months) vs. 47.9% (12 months)
OS 5-year 92.0% (36 months) vs. 81.7% ((12 months) |